A study of Medicare data and US Food and Drug Administration authorizations found that the lengthy coverage period for newly cleared or approved medical devices highlights the need for a new "transitional coverage" pathway.
Zachary Sexton, a bioengineering graduate student at Stanford University, led a group at Stanford that analyzed 281 devices authorized by the FDA from 2016 to 2019
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?